Peter de Bruijn, Stefan Sleijfer, Mei-Ho Lam, Ron H J Mathijssen, Erik A C Wiemer, Walter J Loos. J Pharm Biomed Anal 2010
Times Cited: 38
Times Cited: 38
Times Cited
Times Co-cited
Similarity
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Patton Minkin, Ming Zhao, Zhaoyuan Chen, Jan Ouwerkerk, Hans Gelderblom, Sharyn D Baker. J Chromatogr B Analyt Technol Biomed Life Sci 2008
Patton Minkin, Ming Zhao, Zhaoyuan Chen, Jan Ouwerkerk, Hans Gelderblom, Sharyn D Baker. J Chromatogr B Analyt Technol Biomed Life Sci 2008
42
A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Marie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, Gérard Milano. J Chromatogr B Analyt Technol Biomed Life Sci 2009
Marie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, Gérard Milano. J Chromatogr B Analyt Technol Biomed Life Sci 2009
50
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.
R Honeywell, K Yarzadah, E Giovannetti, N Losekoot, E F Smit, M Walraven, J S W Lind, C Tibaldi, H M Verheul, G J Peters. J Chromatogr B Analyt Technol Biomed Life Sci 2010
R Honeywell, K Yarzadah, E Giovannetti, N Losekoot, E F Smit, M Walraven, J S W Lind, C Tibaldi, H M Verheul, G J Peters. J Chromatogr B Analyt Technol Biomed Life Sci 2010
39
Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.
Qingyu Zhou, James M Gallo. J Pharm Biomed Anal 2010
Qingyu Zhou, James M Gallo. J Pharm Biomed Anal 2010
41
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
A Haouala, B Zanolari, B Rochat, M Montemurro, K Zaman, M A Duchosal, H B Ris, S Leyvraz, N Widmer, L A Decosterd. J Chromatogr B Analyt Technol Biomed Life Sci 2009
A Haouala, B Zanolari, B Rochat, M Montemurro, K Zaman, M A Duchosal, H B Ris, S Leyvraz, N Widmer, L A Decosterd. J Chromatogr B Analyt Technol Biomed Life Sci 2009
36
Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.
Michael Rodamer, Paul W Elsinghorst, Martina Kinzig, Michael Gütschow, Fritz Sörgel. J Chromatogr B Analyt Technol Biomed Life Sci 2011
Michael Rodamer, Paul W Elsinghorst, Martina Kinzig, Michael Gütschow, Fritz Sörgel. J Chromatogr B Analyt Technol Biomed Life Sci 2011
58
Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint, Nadège Castaing, Mireille Canal-Raffin, Nicholas Moore, Karine Titier, Mathieu Molimard. Clin Chim Acta 2011
Stéphane Bouchet, Emmanuelle Chauzit, Dominique Ducint, Nadège Castaing, Mireille Canal-Raffin, Nicholas Moore, Karine Titier, Mathieu Molimard. Clin Chim Acta 2011
36
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Benoit Blanchet, Carole Saboureau, Anne Sophie Benichou, Bertrand Billemont, Fabrice Taieb, Stanislas Ropert, Alain Dauphin, François Goldwasser, Michel Tod. Clin Chim Acta 2009
Benoit Blanchet, Carole Saboureau, Anne Sophie Benichou, Bertrand Billemont, Fabrice Taieb, Stanislas Ropert, Alain Dauphin, François Goldwasser, Michel Tod. Clin Chim Acta 2009
34
Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
N A G Lankheet, M J X Hillebrand, H Rosing, J H M Schellens, J H Beijnen, A D R Huitema. Biomed Chromatogr 2013
N A G Lankheet, M J X Hillebrand, H Rosing, J H M Schellens, J H Beijnen, A D R Huitema. Biomed Chromatogr 2013
34
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini,[...]. J Clin Oncol 2006
Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini,[...]. J Clin Oncol 2006
28
Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.
Lutz Götze, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher. Clin Chim Acta 2012
Lutz Götze, Axel Hegele, Stephan Klaus Metzelder, Harald Renz, Wolfgang Andreas Nockher. Clin Chim Acta 2012
28
Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.
Feng Qiu, Weihua Bian, Jun Li, Zhicheng Ge. Biomed Chromatogr 2013
Feng Qiu, Weihua Bian, Jun Li, Zhicheng Ge. Biomed Chromatogr 2013
78
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Irina Andriamanana, Ines Gana, Bénédicte Duretz, Anne Hulin. J Chromatogr B Analyt Technol Biomed Life Sci 2013
Irina Andriamanana, Ines Gana, Bénédicte Duretz, Anne Hulin. J Chromatogr B Analyt Technol Biomed Life Sci 2013
28
A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Nielka P van Erp, Djoeke de Wit, Henk-Jan Guchelaar, Hans Gelderblom, Trees J Hessing, Jan den Hartigh. J Chromatogr B Analyt Technol Biomed Life Sci 2013
Nielka P van Erp, Djoeke de Wit, Henk-Jan Guchelaar, Hans Gelderblom, Trees J Hessing, Jan den Hartigh. J Chromatogr B Analyt Technol Biomed Life Sci 2013
28
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Val R Adams, Markos Leggas. Clin Ther 2007
Val R Adams, Markos Leggas. Clin Ther 2007
26
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Brett E Houk, Carlo L Bello, Bill Poland, Lee S Rosen, George D Demetri, Robert J Motzer. Cancer Chemother Pharmacol 2010
Brett E Houk, Carlo L Bello, Bill Poland, Lee S Rosen, George D Demetri, Robert J Motzer. Cancer Chemother Pharmacol 2010
26
An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.
L Couchman, M Birch, R Ireland, A Corrigan, S Wickramasinghe, D Josephs, J Spicer, R J Flanagan. Anal Bioanal Chem 2012
L Couchman, M Birch, R Ireland, A Corrigan, S Wickramasinghe, D Josephs, J Spicer, R J Flanagan. Anal Bioanal Chem 2012
26
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Vicki L Goodman, Edwin P Rock, Ramzi Dagher, Roshni P Ramchandani, Sophia Abraham, Jogarao V S Gobburu, Brian P Booth, S Leigh Verbois, David E Morse, Cheng Yi Liang,[...]. Clin Cancer Res 2007
Vicki L Goodman, Edwin P Rock, Ramzi Dagher, Roshni P Ramchandani, Sophia Abraham, Jogarao V S Gobburu, Brian P Booth, S Leigh Verbois, David E Morse, Cheng Yi Liang,[...]. Clin Cancer Res 2007
23
Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.
Rajneet K Oberoi, Rajendar K Mittapalli, James Fisher, William F Elmquist. Chromatographia 2013
Rajneet K Oberoi, Rajendar K Mittapalli, James Fisher, William F Elmquist. Chromatographia 2013
45
Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction.
S Barattè, S Sarati, E Frigerio, C A James, C Ye, Q Zhang. J Chromatogr A 2004
S Barattè, S Sarati, E Frigerio, C A James, C Ye, Q Zhang. J Chromatogr A 2004
21
Molecular basis for sunitinib efficacy and future clinical development.
Sandrine Faivre, George Demetri, William Sargent, Eric Raymond. Nat Rev Drug Discov 2007
Sandrine Faivre, George Demetri, William Sargent, Eric Raymond. Nat Rev Drug Discov 2007
21
Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Nienke A G Lankheet, Christian U Blank, Henk Mallo, Sandra Adriaansz, Hilde Rosing, Jan H M Schellens, Alwin D R Huitema, Jos H Beijnen. J Anal Toxicol 2011
Nienke A G Lankheet, Christian U Blank, Henk Mallo, Sandra Adriaansz, Hilde Rosing, Jan H M Schellens, Alwin D R Huitema, Jos H Beijnen. J Anal Toxicol 2011
32
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, Sharianne G Louie, James G Christensen, Guangmin Li, Randall E Schreck, Tinya J Abrams, Theresa J Ngai, Leslie B Lee,[...]. Clin Cancer Res 2003
Dirk B Mendel, A Douglas Laird, Xiaohua Xin, Sharianne G Louie, James G Christensen, Guangmin Li, Randall E Schreck, Tinya J Abrams, Theresa J Ngai, Leslie B Lee,[...]. Clin Cancer Res 2003
18
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Rana Rais, Ming Zhao, Ping He, Linping Xu, John F Deeken, Michelle A Rudek. Biomed Chromatogr 2012
Rana Rais, Ming Zhao, Ping He, Linping Xu, John F Deeken, Michelle A Rudek. Biomed Chromatogr 2012
58
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Carolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, Carlo L Bello, Jim Li, Charles Baum, Dennis Slamon. Cancer Chemother Pharmacol 2008
Carolyn D Britten, Fairooz Kabbinavar, J Randolph Hecht, Carlo L Bello, Jim Li, Charles Baum, Dennis Slamon. Cancer Chemother Pharmacol 2008
15
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Silvia De Francia, Antonio D'Avolio, Francesca De Martino, Elisa Pirro, Lorena Baietto, Marco Siccardi, Marco Simiele, Silvia Racca, Giuseppe Saglio, Francesco Di Carlo,[...]. J Chromatogr B Analyt Technol Biomed Life Sci 2009
Silvia De Francia, Antonio D'Avolio, Francesca De Martino, Elisa Pirro, Lorena Baietto, Marco Siccardi, Marco Simiele, Silvia Racca, Giuseppe Saglio, Francesco Di Carlo,[...]. J Chromatogr B Analyt Technol Biomed Life Sci 2009
15
Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Milly E de Jonge, Alwin D R Huitema, Jan H M Schellens, Sjoerd Rodenhuis, Jos H Beijnen. Clin Pharmacokinet 2005
Milly E de Jonge, Alwin D R Huitema, Jan H M Schellens, Sjoerd Rodenhuis, Jos H Beijnen. Clin Pharmacokinet 2005
15
Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.
Nienke A G Lankheet, N Steeghs, H Rosing, J H M Schellens, J H Beijnen, A D R Huitema. Ther Drug Monit 2013
Nienke A G Lankheet, N Steeghs, H Rosing, J H M Schellens, J H Beijnen, A D R Huitema. Ther Drug Monit 2013
40
Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry.
Jacek Musijowski, Edyta Piórkowska, Piotr J Rudzki. J Sep Sci 2014
Jacek Musijowski, Edyta Piórkowska, Piotr J Rudzki. J Sep Sci 2014
50
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
13
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Sindy T Kim,[...]. N Engl J Med 2007
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Sindy T Kim,[...]. N Engl J Med 2007
13
13
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Carlo L Bello, Laurie Sherman, Jihao Zhou, Lev Verkh, John Smeraglia, Janessa Mount, Karen J Klamerus. Anticancer Drugs 2006
Carlo L Bello, Laurie Sherman, Jihao Zhou, Lev Verkh, John Smeraglia, Janessa Mount, Karen J Klamerus. Anticancer Drugs 2006
13
Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Bill Speed, Hai-Zhi Bu, William F Pool, Geoffrey W Peng, Ellen Y Wu, Shem Patyna, Carlo Bello, Ping Kang. Drug Metab Dispos 2012
Bill Speed, Hai-Zhi Bu, William F Pool, Geoffrey W Peng, Ellen Y Wu, Shem Patyna, Carlo Bello, Ping Kang. Drug Metab Dispos 2012
13
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
N A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, G A Cirkel, R H J Mathijssen, M P J K Lolkema, J H M Schellens, E E Voest, S Sleijfer, M J A de Jonge,[...]. Br J Cancer 2014
N A G Lankheet, J S L Kloth, C G M Gadellaa-van Hooijdonk, G A Cirkel, R H J Mathijssen, M P J K Lolkema, J H M Schellens, E E Voest, S Sleijfer, M J A de Jonge,[...]. Br J Cancer 2014
13
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Huixin Yu, Neeltje Steeghs, Cynthia M Nijenhuis, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema. Clin Pharmacokinet 2014
Huixin Yu, Neeltje Steeghs, Cynthia M Nijenhuis, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema. Clin Pharmacokinet 2014
13
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Nienke A G Lankheet, Lotte M Knapen, Jan H M Schellens, Jos H Beijnen, Neeltje Steeghs, Alwin D R Huitema. Ther Drug Monit 2014
Nienke A G Lankheet, Lotte M Knapen, Jan H M Schellens, Jos H Beijnen, Neeltje Steeghs, Alwin D R Huitema. Ther Drug Monit 2014
13
Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
Maikel Herbrink, Niels de Vries, Hilde Rosing, Alwin D R Huitema, Bastiaan Nuijen, Jan H M Schellens, Jos H Beijnen. Ther Drug Monit 2016
Maikel Herbrink, Niels de Vries, Hilde Rosing, Alwin D R Huitema, Bastiaan Nuijen, Jan H M Schellens, Jos H Beijnen. Ther Drug Monit 2016
15
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Georgios S Papaetis, Kostas N Syrigos. BioDrugs 2009
Georgios S Papaetis, Kostas N Syrigos. BioDrugs 2009
10
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Walter Fiedler, Hubert Serve, Hartmut Döhner, Michael Schwittay, Oliver G Ottmann, Anne-Marie O'Farrell, Carlo L Bello, Randy Allred, William C Manning, Julie M Cherrington,[...]. Blood 2005
Walter Fiedler, Hubert Serve, Hartmut Döhner, Michael Schwittay, Oliver G Ottmann, Anne-Marie O'Farrell, Carlo L Bello, Randy Allred, William C Manning, Julie M Cherrington,[...]. Blood 2005
10
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
Robert Roskoski. Biochem Biophys Res Commun 2007
Robert Roskoski. Biochem Biophys Res Commun 2007
10
High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
R Bakhtiar, J Lohne, L Ramos, L Khemani, M Hayes, F Tse. J Chromatogr B Analyt Technol Biomed Life Sci 2002
R Bakhtiar, J Lohne, L Ramos, L Khemani, M Hayes, F Tse. J Chromatogr B Analyt Technol Biomed Life Sci 2002
10
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud,[...]. Blood 2007
Stephane Picard, Karine Titier, Gabriel Etienne, Emmanuelle Teilhet, Dominique Ducint, Marie-Agnes Bernard, Regis Lassalle, Gerald Marit, Josy Reiffers, Bernard Begaud,[...]. Blood 2007
10
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Joshua O Haznedar, Shem Patyna, Carlo L Bello, Geoffrey W Peng, William Speed, Xiaoming Yu, Qingling Zhang, Juthamas Sukbuntherng, David J Sweeny, Lida Antonian,[...]. Cancer Chemother Pharmacol 2009
Joshua O Haznedar, Shem Patyna, Carlo L Bello, Geoffrey W Peng, William Speed, Xiaoming Yu, Qingling Zhang, Juthamas Sukbuntherng, David J Sweeny, Lida Antonian,[...]. Cancer Chemother Pharmacol 2009
10
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Richard A Larson, Brian J Druker, Francois Guilhot, Stephen G O'Brien, Gilles J Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang. Blood 2008
Richard A Larson, Brian J Druker, Francois Guilhot, Stephen G O'Brien, Gilles J Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang. Blood 2008
10
Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
Yunsheng Hsieh, Gerica Galviz, Qiao Zhou, Christine Duncan. Rapid Commun Mass Spectrom 2009
Yunsheng Hsieh, Gerica Galviz, Qiao Zhou, Christine Duncan. Rapid Commun Mass Spectrom 2009
21
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Rolf W Sparidans, Tahani T A Ahmed, Eline W Muilwijk, Marieke E B Welzen, Jan H M Schellens, Jos H Beijnen. J Chromatogr B Analyt Technol Biomed Life Sci 2012
Rolf W Sparidans, Tahani T A Ahmed, Eline W Muilwijk, Marieke E B Welzen, Jan H M Schellens, Jos H Beijnen. J Chromatogr B Analyt Technol Biomed Life Sci 2012
28
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Nielka P van Erp, Hans Gelderblom, Henk-Jan Guchelaar. Cancer Treat Rev 2009
Nielka P van Erp, Hans Gelderblom, Henk-Jan Guchelaar. Cancer Treat Rev 2009
10
Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
Nicolas Widmer, Christophe Bardin, Etienne Chatelut, Angelo Paci, Jos Beijnen, Dominique Levêque, Gareth Veal, Alain Astier. Eur J Cancer 2014
10
A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines.
Iris Garrido-Cano, Aurelio García-García, Juan Peris-Vicente, Enrique Ochoa-Aranda, Josep Esteve-Romero. Talanta 2015
Iris Garrido-Cano, Aurelio García-García, Juan Peris-Vicente, Enrique Ochoa-Aranda, Josep Esteve-Romero. Talanta 2015
22
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.